Biomm

Biomm Equity

The The Equity of Biomm (BIOM3.SA) as of Nov 11, 2026 is 313.51 M BRL. In the previous year, The Equity was 262.78 M BRL — a change of 19.30% (higher).

Equity

313.51 MBRL

YoY

19.30%

Last updated:

In 2025, Biomm's equity was 313.51 M BRL, a 19.30% increase from the 262.78 M BRL equity in the previous year.

The Biomm Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
106.09 M BRL
Jan 1, 2019
153.56 M BRL
Jan 1, 2020
191.48 M BRL
Jan 1, 2021
111.59 M BRL
Jan 1, 2022
159.11 M BRL
Jan 1, 2023
122.94 M BRL
Jan 1, 2024
262.78 M BRL
Jan 1, 2025
313.51 M BRL
The Biomm Equity history
YEAREquityYoY
313.51 MBRL+19.30%
262.78 MBRL+113.75%
122.94 MBRL-22.73%
159.11 MBRL+42.59%
111.59 MBRL-41.72%
191.48 MBRL+24.70%
153.56 MBRL+44.74%
106.09 MBRL+78.90%
59.30 MBRL-10.05%
65.93 MBRL-42.73%
115.13 MBRL+7.49%
107.10 MBRL—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biomm Stock analysis

What does Biomm do? Biomm SA generates revenue through the development and licensing of technology for producing human insulin and other recombinant proteins. The company's patented technology, protected in multiple regions, is used by pharmaceutical firms to manufacture therapeutic proteins for drugs and biopharmaceuticals. Its subsidiaries Biomm International Inc, Biomm Middle East Inc, and Biomm Russia Ltd support global operations. The firm also develops production processes for enzymes used in biomass hydrolysis and bio-fuel manufacturing, targeting industrial applications in renewable energy sectors. The primary buyers of Biomm SA's technology are pharmaceutical companies seeking to produce therapeutic proteins. These firms license the company's patented insulin production methods to integrate into their drug manufacturing processes. The enzyme production technology is sold to companies in the bio-fuel industry, particularly those involved in biomass conversion for renewable energy. Biomm SA's focus on recombinant protein production and bio-fuel applications positions it within the biotechnology and renewable energy markets. The company's business model relies on technology licensing fees and sales of proprietary production processes. Insulin production technology, protected by international patents, forms a significant revenue stream. Enzyme technology for biomass hydrolysis and bio-fuel manufacturing provides additional income from industrial clients. Biomm SA's subsidiaries facilitate international market access, enabling the company to serve global clients across pharmaceutical and renewable energy sectors. Biomm is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Biomm's Equity

Biomm's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Biomm's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Biomm's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Biomm's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Biomm’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Biomm stock

The Equity of Biomm is 313.51 M BRL in 2025.

The Equity of Biomm changed from 262.78 M BRL to 313.51 M BRL, representing a 19.30% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Biomm since 2006 – with annual values, charts, and detailed analysis.

The Equity's BRL is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Biomm historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Biomm

All Key Metrics — Biomm